{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/d216e525-3568-4f94-b402-8a3eaa1ad260/636cf48f6c5fb60011855c19?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Morphologic Feature Guiding Discovery of Driver Genetic Alteration in Rare Entity","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9f39f1a8cbe7bbf3cedc6/show-cover.png?height=200","description":"<p>Adenoid Ameloblastoma is a very rare benign odontogenic tumor characterized microscopically by epithelium resembling conventional ameloblastoma, with additional duct-like structures, epithelial whorls, and cribriform architecture. Dentinoid deposits, clusters of clear cells, and ghost-cell keratinization may also be present.These tumors do not harbor BRAF or KRAS mutations and their molecular basis appears distinct from conventional ameloblastoma but remains unknown. <strong>Dr. Carolina Cavalieri Gomes</strong> from the Universidade Federal de Minas Gerais in Brazil, discusses her team’s discovery of <strong>CTNNB1 (beta-catenin)</strong> exon 3 mutations in 4 of 9 primary cases and 2 additional recurrences. </p><p>While the occasional presence of <strong>ghost cells keratinization</strong> was the feature that led the team to initially investigate beta-catinin, this feature was present in only 2/6. Furthermore, nuclear beta-catenin immunoexpression (IHC) was found in 7 of 8 tested samples including some with wild type CTNNB1. The findings support the classification of adenoid ameloblastoma as a separate entity, and not as a subtype of ameloblastoma. The use of beta-catenin IHC could help in establishing the diagnosis in challenging cases.</p>","author_name":"Modern Pathology"}